Eli Lilly and Company $LLY Shares Sold by R Squared Ltd

R Squared Ltd cut its stake in Eli Lilly and Company (NYSE:LLY) by 78.8% during the second quarter, HoldingsChannel reports. The institutional investor owned 560 shares of the company’s stock after selling 2,087 shares during the quarter. R Squared Ltd’s holdings in Eli Lilly and Company were worth $672,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. Schnieders Capital Management LLC. boosted its stake in Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after purchasing an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter worth $356,000. Finally, Nebula Research & Development LLC acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at about $749,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 0.4%

Shares of NYSE LLY opened at $1,184.44 on Tuesday. The company has a market capitalization of $1.11 trillion, a P/E ratio of 39.75, a P/E/G ratio of 1.39 and a beta of 0.51. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a 50 day simple moving average of $1,171.52 and a 200-day simple moving average of $1,053.72. Eli Lilly and Company has a 1 year low of $685.15 and a 1 year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 23.22%.

Analysts Set New Price Targets

Several research firms have recently weighed in on LLY. Weiss Ratings downgraded shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 11th. Guggenheim upped their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research note on Monday, July 13th. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Citigroup increased their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Finally, Barclays boosted their price objective on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,292.18.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide results support higher guidance. Favorable trial results for retatrutide, Lilly’s next-generation obesity and diabetes candidate, reportedly prompted the company to lift its guidance. The update strengthens expectations that Lilly can extend its GLP-1 growth beyond Mounjaro and Zepbound. Eli Lilly Lifts Guidance on Retatrutide Trial Wins
• Positive Sentiment: New OmniAb collaboration expands Lilly’s discovery pipeline. Lilly signed a global collaboration and licensing agreement with OmniAb for an ion-channel drug-discovery program. The deal, which could provide OmniAb with up to $370 million in milestones, gives Lilly access to additional technology and potential future medicines while reinforcing its investment in pipeline development. OmniAb Announces Global Collaboration and License Agreement
• Positive Sentiment: Recent growth catalysts remain intact. Commentary highlights Lilly’s robust second-quarter performance, approximately 48% year-over-year revenue growth, UK regulatory approval, a Medicare access program and continuing GLP-1 demand. Analysts also point to strong momentum and a broad pipeline as reasons for long-term optimism. Eli Lilly’s Growth Story Keeps Adding Chapters
• Neutral Sentiment: Valuation remains debated. A discounted-cash-flow analysis suggests potential upside, but Lilly’s five-year total return of more than 360% and elevated trading multiples mean substantial future growth is already reflected in the stock. Can Eli Lilly Stay Undervalued If Growth Keeps Delivering?
• Negative Sentiment: Competition and pricing risks remain. Analysts view strong GLP-1 momentum favorably but caution that Lilly’s valuation is demanding and competition, pricing pressure and future patent headwinds could limit additional upside. LLY Up After Robust Q2 Results

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.